Literature DB >> 25956073

The risk and outcomes of pneumonia in patients on inhaled corticosteroids.

Oriol Sibila1, Natalia Soto-Gomez2, Marcos I Restrepo3.   

Abstract

Corticosteroids are frequently prescribed anti-inflammatory medications. Inhaled corticosteroids (ICS) are indicated for Chronic Obstructive Pulmonary Disease (COPD) and asthma. ICS are associated with a decrease in exacerbations and improved quality of life in COPD, however multiple studies have linked the chronic use of ICSs with an increased risk of developing pneumonia, though the effect on mortality is unclear. We review the association of ICS with the risk of pneumonia and the implications on clinical outcomes. Published by Elsevier Ltd.

Entities:  

Keywords:  Chronic obstructive pulmonary disease; Inhaled corticosteroids; Pneumonia

Mesh：

Substances：

Year:  2015        PMID： 25956073      PMCID： PMC5079105          DOI： 10.1016/j.pupt.2015.04.001

Source DB:  PubMed          Journal:  Pulm Pharmacol Ther        ISSN： 1094-5539            Impact factor:   3.410


  64 in total

1.  Neuroendocrine regulation of immunity.

Authors:  Jeanette I Webster; Leonardo Tonelli; Esther M Sternberg
Journal:  Annu Rev Immunol       Date:  2001-10-04       Impact factor: 28.527

2.  Observational study of inhaled corticosteroids on outcomes for COPD patients with pneumonia.

Authors:  Dennis Chen; Marcos I Restrepo; Michael J Fine; Mary Jo V Pugh; Antonio Anzueto; Mark L Metersky; Brandy Nakashima; Chester Good; Eric M Mortensen
Journal:  Am J Respir Crit Care Med       Date:  2011-04-21       Impact factor: 21.405

Review 3.  Pharmacokinetics of inhaled drugs.

Authors:  B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  1996-12       Impact factor: 4.335

4.  Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease.

Authors:  Peter Kardos; Marion Wencker; Thomas Glaab; Claus Vogelmeier
Journal:  Am J Respir Crit Care Med       Date:  2006-10-19       Impact factor: 21.405

5.  Prehospital use of inhaled corticosteroids and point prevalence of pneumonia at the time of hospital admission: secondary analysis of a multicenter cohort study.

Authors:  Emir Festic; Vikas Bansal; Ognjen Gajic; Augustine S Lee
Journal:  Mayo Clin Proc       Date:  2014-02       Impact factor: 7.616

6.  Risks of pneumonia in patients with asthma taking inhaled corticosteroids.

Authors:  Paul M O'Byrne; Soren Pedersen; Lars-Göran Carlsson; Finn Radner; Anders Thorén; Stefan Peterson; Pierre Ernst; Samy Suissa
Journal:  Am J Respir Crit Care Med       Date:  2010-10-01       Impact factor: 21.405

7.  Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia.

Authors:  R Malo de Molina; E M Mortensen; M I Restrepo; L A Copeland; M J V Pugh; A Anzueto
Journal:  Eur Respir J       Date:  2010-04-22       Impact factor: 16.671

8.  Global strategy for asthma management and prevention: GINA executive summary.

Authors:  E D Bateman; S S Hurd; P J Barnes; J Bousquet; J M Drazen; J M FitzGerald; P Gibson; K Ohta; P O'Byrne; S E Pedersen; E Pizzichini; S D Sullivan; S E Wenzel; H J Zar
Journal:  Eur Respir J       Date:  2008-01       Impact factor: 16.671

Review 9.  Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis.

Authors:  Sonal Singh; Aman V Amin; Yoon K Loke
Journal:  Arch Intern Med       Date:  2009-02-09

Review 10.  Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease.

Authors:  L Nannini; C J Cates; T J Lasserson; P Poole
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17
View more
  2 in total

1.  Rehospitalization for pneumonia after first pneumonia admission: Incidence and predictors in a population-based cohort study.

Authors:  Paola Faverio; Matteo Monzio Compagnoni; Matteo Della Zoppa; Alberto Pesci; Anna Cantarutti; Luca Merlino; Fabrizio Luppi; Giovanni Corrao
Journal:  PLoS One       Date:  2020-06-30       Impact factor: 3.240

2.  The Effects of Inhaled Airway Directed Pharmacotherapy on Decline in Lung Function Parameters Among Indigenous Australian Adults With and Without Underlying Airway Disease.

Authors:  Subash S Heraganahally; Tarun R Ponneri; Timothy P Howarth; Helmi Ben Saad
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-09-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.